Patients with the urticarial form of BP may never develop typical BP bullae, but continue to exhibit skin lesions typical of urticarial dermatitis (Kossard, Hamann, & Wilkinson, 2006). Histologic ...
Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony had similar, but less severe, lesions. Again, we did not administer ...
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
Treatment should make BP more tolerable to each individual patient through the reduction of blister formation, urticarial lesions, and pruritus. Prior to the use of oral corticosteroids ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results